US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SATELLOS BIOSCIENCE INC.

10.01

-0.1750-1.72%

Post-market: 10.010.00000.00%17:13 EDT

Volume:22.06K

Turnover:219.14K

Market Cap:212.38M

PE:-5.03

High:10.16

Open:10.00

Low:9.80

Close:10.19

52wk High:13.39

52wk Low:5.44

Shares:21.22M

Float Shares:18.02M

Volume Ratio:0.98

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9897

EPS(LYR):-1.7041

ROE:-70.45%

ROA:-41.89%

PB:3.55

PE(LYR):-5.87

Loading ...

Overview Company News Filings

Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate

Benzinga Earnings

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc Expected to Post a Loss of 53 Cents a Share - Earnings Preview

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247

Guggenheim Keeps Their Buy Rating on Satellos Bioscience (MSLE)

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos to Present Clinical Program Updates at ICNMD 2026

Press Release: Satellos Bioscience Announces Results of Annual Meeting of Shareholders

Satellos to Participate in Upcoming Investor Conferences

Satellos resumed with a Speculative Buy at Canaccord

Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY

Benzinga Earnings

Press Release: Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc expected to post a loss of 69 cents a share - Earnings Preview

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Leerink Partners Initiates Satellos Bioscience at Outperform

MT Newswires Live

Satellos initiated with an Outperform at Leerink

Satellos Bioscience Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $20

THOMSON REUTERS

Press Release: Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Calendar of U.S. Earnings Expected in the Week Ahead

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/MSLE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSLE\",,,,,undefined,":{"symbol":"MSLE","market":"US","secType":"STK","nameCN":"SATELLOS BIOSCIENCE INC.","latestPrice":10.01,"timestamp":1787342400000,"preClose":10.185,"halted":0,"volume":22055,"hourTrading":{"tag":"盘后","latestPrice":10.01,"preClose":10.01,"latestTime":"17:13 EDT","volume":3005,"amount":29496.433,"timestamp":1787346826449,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017182130584192507,"floatShares":18023800,"shares":21216400,"eps":-1.989732,"marketStatus":"Market Closed","change":-0.175,"latestTime":"08-21 16:00:00 EDT","open":10,"high":10.155,"low":9.8,"amount":219141.39126,"amplitude":0.034855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.989732,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":10.185,"postHourTrading":{"tag":"盘后","latestPrice":10.01,"preClose":10.01,"latestTime":"17:13 EDT","volume":3005,"amount":29496.433,"timestamp":1787346826449,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.982790589491752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSLE\",,,,,undefined,":{"symbol":"MSLE","floatShares":18023800,"roa":"-41.89%","roe":"-70.45%","lyrEps":-1.704123,"volumeRatio":0.982790589491752,"shares":21216400,"dividePrice":0,"high":10.155,"amplitude":0.034855,"preClose":10.185,"low":9.8,"week52Low":5.44,"pbRate":"3.55","week52High":13.3949,"institutionHeld":0,"latestPrice":10.01,"eps":-1.989732,"divideRate":0,"volume":22055,"delay":0,"ttmEps":-1.989732,"open":10,"prevYearClose":12.5,"prevWeekClose":9.61,"prevMonthClose":9.99,"prevQuarterClose":7.775,"fiveDayClose":9.61,"twentyDayClose":9.78,"sixtyDayClose":7.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MSLE","fiscalQuarterEnding":"2026/06","expectedEps":-0.38,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2026-05-15","symbol":"MSLE","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2026-03-27","symbol":"MSLE","fiscalQuarterEnding":"2025/12","expectedEps":-0.36,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-0.47},{"market":"US","date":"2026-02-06","symbol":"MSLE","reason":null,"defaultRemindTime":1770388200000,"announcedDate":"2026-02-05","type":"delisting","dateTimestamp":1770354000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MSLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1779336000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MSLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MSLE","date":"2026-08-21","current":-5.030828,"percent":0.548872,"low":-12.479818,"twenty":-7.441354,"median":-6.336309,"eighty":-5.090602,"high":-4.052556,"avg":-6.824003,"sd":2.148211,"marketCap":212720451},"quantilePoints":[{"date":"2026-02-13","current":-10.770362,"twenty":-10.948162,"median":-10.770362,"eighty":-10.650272,"marketCap":232264709.51},{"date":"2026-02-20","current":-10.655876,"twenty":-10.961105,"median":-10.795625,"eighty":-10.660269,"marketCap":229795787.77},{"date":"2026-02-27","current":-11.410036,"twenty":-11.040635,"median":-10.847134,"eighty":-10.698718,"marketCap":246059372.56},{"date":"2026-03-06","current":-11.830077,"twenty":-11.717077,"median":-10.918938,"eighty":-10.750564,"marketCap":255117626.85},{"date":"2026-03-13","current":-8.109914,"twenty":-11.50908,"median":-10.908981,"eighty":-10.660269,"marketCap":174891683.43},{"date":"2026-03-20","current":-7.707011,"twenty":-11.414276,"median":-10.795625,"eighty":-8.641353,"marketCap":166203013.02},{"date":"2026-03-27","current":-6.631132,"twenty":-11.347113,"median":-10.74587,"eighty":-7.112164,"marketCap":143001488.38},{"date":"2026-04-02","current":-5.025579,"twenty":-11.228066,"median":-10.659537,"eighty":-6.857362,"marketCap":125001211.63},{"date":"2026-04-10","current":-5.215911,"twenty":-11.093473,"median":-9.47912,"eighty":-5.796539,"marketCap":129735363.26},{"date":"2026-04-17","current":-7.29856,"twenty":-11.048776,"median":-7.908462,"eighty":-5.702641,"marketCap":181537079.31},{"date":"2026-04-24","current":-5.815307,"twenty":-10.982188,"median":-7.307008,"eighty":-5.899657,"marketCap":144644124.23},{"date":"2026-05-01","current":-6.614029,"twenty":-10.910972,"median":-7.101939,"eighty":-6.007657,"marketCap":164510727.14},{"date":"2026-05-08","current":-6.017774,"twenty":-10.898871,"median":-6.946772,"eighty":-6.020777,"marketCap":149680075.96},{"date":"2026-05-15","current":-6.08008,"twenty":-10.857436,"median":-6.796189,"eighty":-6.025643,"marketCap":151229840.1},{"date":"2026-05-22","current":-5.211571,"twenty":-10.78552,"median":-6.687256,"eighty":-5.618291,"marketCap":148529791.46},{"date":"2026-05-29","current":-5.103954,"twenty":-10.770158,"median":-6.614029,"eighty":-5.255741,"marketCap":145462670.32},{"date":"2026-06-05","current":-4.363978,"twenty":-10.759953,"median":-6.487368,"eighty":-5.212439,"marketCap":124373364.94},{"date":"2026-06-12","current":-4.185836,"twenty":-10.710558,"median":-6.372119,"eighty":-5.089985,"marketCap":119296318.27},{"date":"2026-06-18","current":-4.199227,"twenty":-10.663198,"median":-6.287103,"eighty":-5.025579,"marketCap":119677976.75},{"date":"2026-06-26","current":-4.954335,"twenty":-10.655876,"median":-6.142163,"eighty":-4.954335,"marketCap":141198553.46},{"date":"2026-07-02","current":-5.492609,"twenty":-10.610029,"median":-6.104011,"eighty":-4.962096,"marketCap":156539367.39},{"date":"2026-07-10","current":-6.851463,"twenty":-9.703009,"median":-6.103353,"eighty":-4.972873,"marketCap":195266674.43},{"date":"2026-07-17","current":-6.330872,"twenty":-9.09234,"median":-6.142163,"eighty":-4.987412,"marketCap":180429849.49},{"date":"2026-07-24","current":-7.10048,"twenty":-8.28706,"median":-6.175449,"eighty":-5.018562,"marketCap":202363679},{"date":"2026-07-31","current":-6.948117,"twenty":-7.868172,"median":-6.287103,"eighty":-5.045112,"marketCap":198021331.41},{"date":"2026-08-07","current":-7.490033,"twenty":-7.686916,"median":-6.336309,"eighty":-5.066565,"marketCap":213465959.75},{"date":"2026-08-14","current":-7.261635,"twenty":-7.563428,"median":-6.389315,"eighty":-5.08268,"marketCap":206956595.44},{"date":"2026-08-21","current":-6.146213,"twenty":-7.441354,"median":-6.336309,"eighty":-5.090602,"marketCap":212720451}],"updateTime":1787503580759},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSLE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659779160","title":"Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659779160","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659779160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:04","pubTimestamp":1786655045,"startTime":"0","endTime":"0","summary":"Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses of $(0.39) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61196467/satellos-bioscience-q2-eps-0-56-misses-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4139","PRGS","IDNA","BMED","IND","NVIB","BK4097","MEDX","MSLE","LU2065732104.USD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655615483","title":"Satellos Bioscience Inc Expected to Post a Loss of 53 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2655615483","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655615483?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:18","pubTimestamp":1785503899,"startTime":"0","endTime":"0","summary":"Satellos Bioscience Inc <MSCL.TO> expected to post a loss of53cents a share - Earnings PreviewSatellos Bioscience IncMSCL.TOis expected to  report resultson August 4 (estimated) for the period ending ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X1Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929985","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929985?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:40","pubTimestamp":1783597212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), Satellos Bioscience (MS...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-satellos-bioscience-msle-and-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-satellos-bioscience-msle-and-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KBWB","LU0128526141.USD","LU1668664300.SGD","LU1951200564.SGD","EKG","LU2265009873.SGD","MSLE","LU0234570918.USD","IE00BYQQ9H92.USD","LU0971096721.USD","LU0823416689.USD","IE00BJJMRZ35.SGD","LU1244550577.SGD","LU1061106388.HKD","IDNA","LGHT","PTH","LU0079474960.USD","LU0795875169.SGD","LU0795875086.SGD","IE0002141913.USD","LU1923622614.USD","LU0061475181.USD","LU1720051017.SGD","ISRG","LU0267386448.USD","LU0029874061.USD","LU1868836914.USD","IHI","BBH","LU2433249047.HKD","RVMD","XBI","CANC","LU2106854487.HKD","LU2023250843.SGD","LU2111349929.HKD","LU0390134368.USD","LU0557290698.USD","LU0889565916.HKD","LU1244550494.USD","ISUL","IE00B4R5TH58.HKD","LABU","LU1057294990.SGD","IAI","LU1363072403.SGD","LU0158827781.USD","HCSG","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649606759","title":"Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2649606759","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649606759?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:30","pubTimestamp":1783506600,"startTime":"0","endTime":"0","summary":"All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3323924/0/en/Satellos-Reports-Six-Month-Interim-TRAILHEAD-Data-Showing-Reduced-Muscle-Fat-Fraction-Increased-Effort-Stable-Strength-Lower-CK-and-Favorable-Safety-Profile-in-DMD-Adults-Treated-w.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BMED","SAT","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647255310","title":"Guggenheim Keeps Their Buy Rating on Satellos Bioscience (MSLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647255310","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647255310?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:45","pubTimestamp":1782819952,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on Satellos Bioscience today and set a price target of $23.00. Chattopadhyay covers...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-satellos-bioscience-msle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-satellos-bioscience-msle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647437658","title":"Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647437658","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647437658?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730800,"startTime":"0","endTime":"0","summary":"SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”)Fast Track is designed to expedite the development/re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318825/0/en/Satellos-Receives-FDA-Fast-Track-Designation-for-SAT-3247-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4588","LABU","BK4139","BK4585","SAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646087233","title":"Satellos to Present Clinical Program Updates at ICNMD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646087233","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646087233?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385200,"startTime":"0","endTime":"0","summary":"TORONTO, June  25, 2026  (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317398/0/en/Satellos-to-Present-Clinical-Program-Updates-at-ICNMD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644615724","title":"Press Release: Satellos Bioscience Announces Results of Annual Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2644615724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644615724?lang=en_us&edition=fundamental","pubTime":"2026-06-18 05:00","pubTimestamp":1781730000,"startTime":"0","endTime":"0","summary":"TORONTO, June 17, 2026  -- Satellos Bioscience Inc.  , a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 .Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026  were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company.Director              Votes For  % For  Votes Against  % Against. Please refer to Circular available on SEDAR+  and EDGAR  for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to reset the body's natural muscle repai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638504934","title":"Satellos to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638504934","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638504934?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"TORONTO, May  27, 2026  (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301758/0/en/Satellos-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637933833","title":"Satellos resumed with a Speculative Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2637933833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637933833?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:18","pubTimestamp":1779362281,"startTime":"0","endTime":"0","summary":"Canaccord analyst Tania Armstrong-Whitworth resumed coverage of Satellos (MSLE) with a Speculative Buy rating and C$19 price target The company’s l...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-resumed-with-a-speculative-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-resumed-with-a-speculative-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608618","title":"Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608618","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608618?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:09","pubTimestamp":1778843373,"startTime":"0","endTime":"0","summary":"Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52591899/satellos-bioscience-q1-eps-0-53-down-from-0-44-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","BK4139","QLD","QQQY","IYW","JEPQ","QQQJ","MNQmain","ONEQ","NVIW.SI","PSQ","NDX","QID",".IXIC","NQmain","GPIQ","FTEC","QQQA","TQQY","QQQE","QQQM","QQQ","MSLE","QYLG","TQQQ","TECS","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635865350","title":"Press Release: Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635865350","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635865350?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":"-- Eleven clinical trial sites in BASECAMP currently active; remaining. -- BASECAMP remains on track to complete enrollment in Q3 2026. -- The Company has initiated the TRAILHEAD study in the U.S. in adults aged. -- Current cash available of $69.9M  provides runway through. \"The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted to Nasdaq, and advanced the Phase 2 TRAILHEAD and BASECAMP studies,\" said Frank Gleeson, MBA, Chief Executive Officer of Satellos. \"We are excited by the progress we are making with BASECAMP enrollment and dosing across 11 active clinical sites to date. We expect the additional sites intended to complete BASECAMP to be activated in Q2. We remain on track to complete BASECAMP enrollment in Q3 2026, supported by the active and planned sites currently having identified more than 100% of potential participants for screening and potential enrollment in the coming","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","MSLE","LU2065732104.USD","BK4097","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632617866","title":"Satellos Bioscience Inc  expected to post a loss of 69 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632617866","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632617866?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:10","pubTimestamp":1777641007,"startTime":"0","endTime":"0","summary":"Satellos Bioscience Inc  expected to post a loss of69cents a share - Earnings Preview Satellos Bioscience Inc MSCL.TO  is expected to  report resultson May 4 (estimated) for the period ending March 31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186290","title":"Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186290","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186290?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"TORONTO, April  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270787/0/en/Satellos-to-Present-at-the-Bloom-Burton-Co-Healthcare-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0128526141.USD","LABU","XBI","BK4585","BK4588","HCSG","LU0029874061.USD","BK4139","BK4137","XLV","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625679872","title":"Leerink Partners Initiates Satellos Bioscience at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625679872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625679872?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:50","pubTimestamp":1775476234,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Satellos Bioscience at Outperform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625751676","title":"Satellos initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2625751676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625751676?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:41","pubTimestamp":1775472087,"startTime":"0","endTime":"0","summary":"Leerink initiated coverage of Satellos (MSLE) with an Outperform rating and $20 price target The firm believes Satellos represents a differentiated...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625737686","title":"Satellos Bioscience Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2625737686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625737686?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:09","pubTimestamp":1775470189,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P080:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622856823","title":"Press Release: Satellos Reports 2025 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2622856823","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622856823?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609200,"startTime":"0","endTime":"0","summary":"-- Completed a US$57.2 million equity financing; commenced trading on the. Nasdaq Global Market under the ticker \"MSLE\" on Feb. 6, 2026. -- Secured global regulatory clearances and initiated BASECAMP, a. placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to. less than 10 years living with Duchenne muscular dystrophy (\"Duchenne\" or. -- Presented initial functional outcomes from 56 days of treatment in. grip strength improvements observed in CL-101 were maintained or improved. in TRAILHEAD over an aggregate period of 9 to 13 months. -- Reported proteomic data from CL-101 (28-day Phase 1b trial in adults with. DMD) at MDA, showing reductions in established biomarkers of muscle. -- Presented validation of a Regenerative Index  biomarker at MDA,treatment and inform clinical interpretation; also presented new. BASECAMP is a global, randomized, placebo-controlled Phase 2 clinical trial in DMD evaluating safety, biomarkers and treatment effect of SAT-3247 over three months in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDA","LU1236620750.USD","LU2463526074.USD","MSLE","LU0070302665.USD","BK4533","CL","BK4097","LU1150488135.SGD","LU0208291251.USD","LU1571399168.USD","LU2125154778.USD","LU0731783394.SGD","LU1150488218.USD","LU2065732104.USD","BK4018","LU2108987350.USD","LU1675838814.USD","LU1941712348.USD","BK4504","LU1585245621.USD","BK4588","LU0320765489.SGD","LU1430594728.SGD","BK4585","LU1236620834.HKD","LU2360032135.SGD","LU0266013472.USD","PRGS","BK4532","LU0985320562.USD","LU2125154935.USD","LU0323591593.USD","SG9999001440.SGD","BK4187","BK4139","LU1941712264.USD","LU0345770308.USD","LU1599440770.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYND","BEEM","FDS","AUTL","BTBT","LW","KEEL","DEFT","PRGS","NKLR","BITF","ANGO","BCAX","HUMA","NMRA","ATOS","CCL","INV","NEOG","BIRD","AIRJ","APOG","FC","LNN","MKC","IMNN","KYTX","AIRO","NCNO","RNXT","JILL","CRDL","NKE","PENG","PLAY","CAG","DMAC","KOPN","INMB","BHST","MSM","MKC.V","AEHR","CALM","AYI","NGEN","MSLE","AURA","LGN","PHR","BNZI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}